Table 2.
SIR Analysis of SPLCs in Patients with a History of an IPLC by Sex, Race, Age, and Year of Diagnosis, 1992-2007 with Follow-up through 2012, SEER-13
| Characteristic | Observed | Expected | Observed/Expected | 95% CI | |
|---|---|---|---|---|---|
| Total | 4622 | 1161.6 | 3.98 | 3.87 | 4.1 |
| Sex and race | |||||
| All men | 2318 | 686.7 | 3.38 | 3.24 | 3.52 |
| White men | 1903 | 548.4 | 3.47 | 3.32 | 3.63 |
| Black men | 247 | 86 | 2.87 | 2.53 | 3.25 |
| Men of other race | 168 | 50.8 | 3.31 | 2.83 | 3.85 |
| All women | 2304 | 474.9 | 4.85 | 4.66 | 5.05 |
| White women | 1938 | 413.7 | 4.68 | 4.48 | 4.9 |
| Black women | 234 | 39.7 | 5.9 | 5.17 | 6.7 |
| Women of other race | 132 | 20.5 | 6.43 | 5.38 | 7.62 |
| Age at diagnosis, y | |||||
| 20–49 | 245 | 19.2 | 12.74 | 11.19 | 14.44 |
| 50–59 | 958 | 136.5 | 7.02 | 6.58 | 7.48 |
| 60–69 | 1920 | 429.1 | 4.47 | 4.28 | 4.68 |
| >70 | 1499 | 576.7 | 2.6 | 2.47 | 2.73 |
| Age (y) and sex | |||||
| Men | |||||
| 20–49 | 108 | 10.3 | 10.53 | 8.64 | 12.71 |
| 50–59 | 467 | 79.4 | 5.88 | 5.36 | 6.44 |
| 60–69 | 987 | 256.6 | 3.85 | 3.61 | 4.09 |
| >70 | 756 | 340.5 | 2.22 | 2.07 | 2.38 |
| Women | |||||
| 20–49 | 137 | 9 | 15.26 | 12.81 | 18.04 |
| 50–59 | 491 | 57.1 | 8.6 | 7.85 | 9.39 |
| 60–69 | 933 | 172.6 | 5.41 | 5.07 | 5.77 |
| >70 | 743 | 236.3 | 3.14 | 2.92 | 3.38 |
| Histologic type | |||||
| Squamous cell | 1265 | 293.83 | 4.31 | 4.07 | 4.55 |
| SCLC | 229 | 66.63 | 3.44 | 3.01 | 3.91 |
| Adenocarcinoma | 2335 | 512.08 | 4.56 | 4.38 | 4.75 |
| Other NSCLC | 793 | 289.06 | 2.74 | 2.56 | 2.94 |
| SEER stage | |||||
| Local | 2561 | 539.98 | 4.74 | 4.56 | 4.93 |
| Regional | 1603 | 392.77 | 4.08 | 3.88 | 4.29 |
| Distant | 335 | 163.17 | 2.05 | 1.84 | 2.29 |
| Unstaged | 123 | 65.68 | 1.87 | 1.56 | 2.23 |
| Year of diagnosis | |||||
| 1992–1996 | 1505 | 427.3 | 3.52 | 3.35 | 3.7 |
| 1997–2001 | 1483 | 378.1 | 3.92 | 3.73 | 4.13 |
| 2002–2007 | 1634 | 356.2 | 4.59 | 4.37 | 4.82 |
| Year and sex | |||||
| Men | |||||
| 1992–1996 | 816 | 268.4 | 3.04 | 2.84 | 3.26 |
| 1997–2001 | 729 | 221 | 3.3 | 3.06 | 3.55 |
| 2002–2007 | 773 | 197.3 | 3.92 | 3.65 | 4.2 |
| Women | |||||
| 1992–1996 | 689 | 158.9 | 4.34 | 4.02 | 4.67 |
| 1997–2001 | 754 | 157.1 | 4.8 | 4.46 | 5.16 |
| 2002–2007 | 861 | 158.9 | 5.42 | 5.06 | 5.79 |
SIR, standardized incidence ratio; SPLC, second primary lung cancer; IPLC, initial primary lung cancer; SEER, Surveillance, Epidemiology, and End Results; CI, confidence interval.